FBP003

FBP003 is a preclinical-stage monoclonal antibody developed by FasT Biopharma. It is part of a pipeline of highly potent antibodies targeting Fas Ligand (FasL), a cytokine that triggers apoptosis (programmed cell death) upon binding to its receptor, Fas (CD95). While other candidates in the FasT Biopharma pipeline are being developed for ophthalmic conditions (FBP001) and oncology (FBP002), FBP003 is currently in the hit identification phase for unspecified "other diseases." The therapeutic rationale involves blocking FasL-mediated signaling to prevent pathological cell death or immune dysregulation associated with various disease states.